BACKGROUND: Mutations in the genes inhA, katG, and rpoB confer resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin. We questioned whether specific mutations in these genes were associated with different clinical and microbiological characteristics. METHODS: In a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rpoB mutations in sputum isolates using the Hain MTBDRplus line probe assay. For specific mutations, we performed bivariate analysis to determine relative risk of baseline or acquired resistance to other TB drugs. We compared time to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression. RESULTS: In total, 447 participants enrolled from January 2005 to December 2008 from 7 countries were included. Relative to rpoB S531L, isolates with rpoB D516V had less cross-resistance to rifabutin, increased baseline resistance to other drugs, and increased acquired fluoroquinolone resistance. Relative to mutation of katG only, mutation of inhA promoter and katG was associated with baseline extensively drug resistant (XDR) TB, increased acquired fluoroquinolone resistance, and slower TSCC (125.5 vs 89.0 days). CONCLUSIONS: Specific mutations in inhA and katG are associated with differences in resistance to other drugs and TSCC. Molecular testing may make it possible to tailor treatment and assess additional drug resistance risk according to specific mutation profile. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Mutations in the genes inhA, katG, and rpoB confer resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin. We questioned whether specific mutations in these genes were associated with different clinical and microbiological characteristics. METHODS: In a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rpoB mutations in sputum isolates using the Hain MTBDRplus line probe assay. For specific mutations, we performed bivariate analysis to determine relative risk of baseline or acquired resistance to other TB drugs. We compared time to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression. RESULTS: In total, 447 participants enrolled from January 2005 to December 2008 from 7 countries were included. Relative to rpoB S531L, isolates with rpoB D516V had less cross-resistance to rifabutin, increased baseline resistance to other drugs, and increased acquired fluoroquinolone resistance. Relative to mutation of katG only, mutation of inhA promoter and katG was associated with baseline extensively drug resistant (XDR) TB, increased acquired fluoroquinolone resistance, and slower TSCC (125.5 vs 89.0 days). CONCLUSIONS: Specific mutations in inhA and katG are associated with differences in resistance to other drugs and TSCC. Molecular testing may make it possible to tailor treatment and assess additional drug resistance risk according to specific mutation profile. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
culture conversion; drug resistance; isoniazid; rifampin; second-line drugs tuberculosis
Authors: Vadim Molodtsov; Nathan T Scharf; Maxwell A Stefan; George A Garcia; Katsuhiko S Murakami Journal: Mol Microbiol Date: 2017-01-10 Impact factor: 3.501
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: I Bouzouita; A M Cabibbe; A Trovato; H Draoui; A Ghariani; B Midouni; L Essalah; E Mehiri; D M Cirillo; L Slim-Saidi Journal: Int J Tuberc Lung Dis Date: 2018-06-01 Impact factor: 2.373
Authors: Ivy Rukasha; Halima M Said; Shaheed V Omar; Hendrik Koornhof; Andries W Dreyer; Alfred Musekiwa; Harry Moultrie; Anwar A Hoosen; Gilla Kaplan; Dorothy Fallows; Nazir Ismail Journal: Front Microbiol Date: 2016-12-05 Impact factor: 5.640
Authors: Caroline Allix-Béguec; Irena Arandjelovic; Lijun Bi; Patrick Beckert; Maryline Bonnet; Phelim Bradley; Andrea M Cabibbe; Irving Cancino-Muñoz; Mark J Caulfield; Angkana Chaiprasert; Daniela M Cirillo; David A Clifton; Iñaki Comas; Derrick W Crook; Maria R De Filippo; Han de Neeling; Roland Diel; Francis A Drobniewski; Kiatichai Faksri; Maha R Farhat; Joy Fleming; Philip Fowler; Tom A Fowler; Qian Gao; Jennifer Gardy; Deborah Gascoyne-Binzi; Ana-Luiza Gibertoni-Cruz; Ana Gil-Brusola; Tanya Golubchik; Ximena Gonzalo; Louis Grandjean; Guangxue He; Jennifer L Guthrie; Sarah Hoosdally; Martin Hunt; Zamin Iqbal; Nazir Ismail; James Johnston; Faisal M Khanzada; Chiea C Khor; Thomas A Kohl; Clare Kong; Sam Lipworth; Qingyun Liu; Gugu Maphalala; Elena Martinez; Vanessa Mathys; Matthias Merker; Paolo Miotto; Nerges Mistry; David A J Moore; Megan Murray; Stefan Niemann; Shaheed V Omar; Rick T-H Ong; Tim E A Peto; James E Posey; Therdsak Prammananan; Alexander Pym; Camilla Rodrigues; Mabel Rodrigues; Timothy Rodwell; Gian M Rossolini; Elisabeth Sánchez Padilla; Marco Schito; Xin Shen; Jay Shendure; Vitali Sintchenko; Alex Sloutsky; E Grace Smith; Matthew Snyder; Karine Soetaert; Angela M Starks; Philip Supply; Prapat Suriyapol; Sabira Tahseen; Patrick Tang; Yik-Ying Teo; Thuong N T Thuong; Guy Thwaites; Enrico Tortoli; Dick van Soolingen; A Sarah Walker; Timothy M Walker; Mark Wilcox; Daniel J Wilson; David Wyllie; Yang Yang; Hongtai Zhang; Yanlin Zhao; Baoli Zhu Journal: N Engl J Med Date: 2018-09-26 Impact factor: 91.245